– Findings Point to Potential Therapeutic Targets –
CAMBRIDGE, Mass. & NEW YORK & HUNTSVILLE, Ala.--(BUSINESS WIRE)--Using advanced DNA sequencing methods, an international consortium that includes scientists and clinicians from Columbia University Medical Center (CUMC), Biogen Idec (NASDAQ: BIIB) and HudsonAlpha Institute for Biotechnology has identified a new gene that is associated with sporadic amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. The newly associated gene, called TBK1 (TANK-Binding Kinase 1), plays a key role at the intersection of two essential cellular pathways: inflammation (a reaction to injury or infection) and autophagy (a cellular process involved in the removal of damaged cellular components). The study was published today in the online edition of Science.
ALS is a devastating neurodegenerative disorder that results in the loss of all voluntary movement and is fatal in the majority of cases. The next-generation genetic sequencing of the exomes (protein-coding portions) of 2,874 ALS patients and 6,405 controls represents the largest number of ALS patients to have been sequenced in a single study to date. Though much is known about the genetic underpinnings of familial ALS, only a handful of genes have been definitively linked to sporadic ALS, which accounts for about 90 percent of all ALS cases.
“The identification of TBK1 is exciting for understanding ALS pathogenesis, especially since the inflammatory and autophagy pathways have been previously implicated in the disease,” said Lucie Bruijn, Ph.D., chief scientist for The ALS Association. “The fact that TBK1 accounts for one percent of ALS adds significantly to our growing understanding of the genetic underpinnings of the disease. This study, which combines the efforts of over two dozen laboratories in six countries, also highlights the global and collaborative nature of ALS research today.”
“This study shows us that large-scale genetic studies can not only work very well in ALS, but that they can help pinpoint key biological pathways relevant to ALS that then become the focus of targeted drug development efforts,” said study co-leader David B. Goldstein, Ph.D., professor of genetics and development and director of the new Institute for Genomic Medicine at CUMC. “ALS is an incredibly diverse disease, caused by dozens of different genetic mutations, which we’re only beginning to discover. The more of these mutations we identify, the better we can decipher – and influence – the pathways that lead to disease.” The other co-leaders of the study are Richard M. Myers, Ph.D., president and scientific director of HudsonAlpha, and Tim Harris, Ph.D., D.Sc., senior vice president of technology and translational sciences at Biogen Idec.
“These findings demonstrate the power of exome sequencing in the search for rare variants that predispose individuals to disease and that identify potential points of intervention. We are looking at the function of this pathway so that one day this research may benefit the patients living with ALS,” said Dr. Harris. “The speed with which we were able to identify this pathway and begin our next phase of research shows the potential of novel, focused collaborations with the best academic scientists to advance our understanding of the molecular pathology of disease. This synergy is vital for both the industry and the academic community, especially in the context of precision medicine and whole-genome sequencing.”
“Industry and academia often do things together, but this is a perfect example of a large, complex project that required many parts, with equal contributions from Biogen Idec: Dr. Harris, our collaborator there, and his team, as well as Dr. Goldstein and his team, now at Columbia University, as well as our teams here at HudsonAlpha,” said Dr. Myers. “I love this research model because it doesn’t happen very frequently, and it really shows how industry, nonprofits and academic laboratories can all work together for the betterment of humankind. The combination of those groups with a large number of the clinical collaborators who have been seeing patients with this disease for many years and providing clinical information, recruiting patients, as well as collecting DNA samples for us to do this study, were all critical to get this done.”
Searching through the enormous database generated in the ALS study, Goldstein and his colleagues found several genes that appear to contribute to ALS, most notably TBK1, which had not been detected in previous, smaller-scale studies. TBK1 mutations appeared in about one percent of the ALS patients – a large proportion in the context of a complex disease with multiple genetic components, according to Goldstein. The study also found that a gene, called OPTN, previously thought to play a minor role in ALS, may actually be a major player in the disease.
“Remarkably, the TBK1 protein and optineurin, which is encoded by the OPTN gene, interact physically and functionally. Both proteins are required for the normal function of inflammatory and autophagy pathways, and now we have shown that mutations in either gene are associated with ALS,” said Goldstein. “Thus there seems to be no question that aberrations in the pathways that require TBK1 and OPTN are important in some ALS patients.”
The researchers are currently using patient-derived, induced pluripotent embryonic stem cells (iPS cells) and mouse models with mutations in TBK1 or OPTN to study ALS disease mechanisms and to screen for drug candidates. Several compounds that affect TBK1 signaling have already been developed for use in cancer, where the gene is thought to play a role in tumor cell survival.
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com.
About Columbia University Medical Center
Columbia University Medical Center provides international leadership in basic, preclinical and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.
About HudsonAlpha Institute for Biotechnology
HudsonAlpha Institute for Biotechnology is a genomic science and applications nonprofit organization. It is both a high-volume genomic data producer serving hundreds of academic, clinical, and commercial clients’ needs and a global scientific collaborator valued for its genomic data analysis and interpretation to solve some of the most pressing questions in cancer, undiagnosed disease, neuro-psychiatric disorders, immune-mediated disease, agriculture and public health. Its unique 152-acre campus melds the boundaries between nonprofit scientists, educators and commercial business people so that collaboration sparks innovation and growth.
Safe Harbor Statement
This press release contains forward-looking statements, including statements about Biogen Idec’s expectations and mission to develop new therapies for people with ALS, through its collaboration with Columbia University Medical Center and/or HudsonAlpha Institute. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including risks and uncertainties associated with drug development and commercialization, Biogen Idec’s dependence on third parties over which it may not always have full control, and the other risks and uncertainties that are described in the Risk Factors section of Biogen Idec’s most recent annual or quarterly report filed with the Securities and Exchange Commission. These statements are based on current beliefs and expectations and speak only as of the date of this press release. Biogen Idec does not undertake any obligation to publicly update any forward-looking statements.